|
Thursday, December 7, 2023, 7:15 PM – 8:45 PM CT (8:15 PM – 9:45 PM ET) | San Antonio, Texas
Beyond the Guidelines: Clinical Investigator Perspectives on the Management of HER2-Low Breast CancerPart 3 of a 3-Part CME Satellite Symposium Series in Partnership with the 2023 San Antonio Breast Cancer Symposium®
Location
San Antonio Marriott Rivercenter 101 Bowie St San Antonio, Texas Hotel Phone: (210) 223-1000 Program Schedule — Central Time 7:00 PM – 7:15 PM — Registration 7:15 PM – 8:45 PM — Dinner Meeting Meeting Room Grand Ballroom G-M (Third Floor) This event will also be webcast live. Please see Registration tab for details. Faculty
Aditya Bardia, MD, MPH Director Breast Cancer Research Program Associate Professor Harvard Medical School Attending Physician Massachusetts General Hospital Boston, Massachusetts Lisa A Carey, MD, ScM, FASCO L Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research Deputy Director for Clinical Sciences Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill, North Carolina Shanu Modi, MD Member and Attending Breast Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell Medical College New York, New York Professor Peter Schmid, FRCP, MD, PhD Lead, Centre of Experimental Cancer Medicine Barts Cancer Institute London, United Kingdom Moderator Neil Love, MD Research To Practice Miami, Florida This symposium is sponsored by Research To Practice and supported by grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc. This is not an official program of the San Antonio Breast Cancer Symposium®.
Program Schedule — Central Time
7:00 PM – 7:15 PM — Registration 7:15 PM – 8:45 PM — Dinner Meeting MODULE 1: Optimal Approaches to HER2 Testing for the Identification of HER2-Low Breast Cancer — Dr Carey
MODULE 2: Available Data with and Current Role of HER2-Targeted Therapy for HER2-Low Disease — Dr Modi
MODULE 3: Identification and Management of Toxicities with T-DXd — Prof Schmid
MODULE 4: Future Directions in the Management of HER2-Low Breast Cancer — Dr Bardia
Target Audience
CME Credit Form FACULTY — Dr Carey has no relevant conflicts of interest to disclose. The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process: Dr Bardia — Consulting Agreements and Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Group, Merck, Novartis, Pfizer Inc, Radius Health Inc, Sanofi. Dr Modi — Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Seagen Inc. Prof Schmid — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Medivation Inc, a Pfizer Company, Novartis, OncoGenex Pharmaceuticals Inc, Roche Laboratories Inc. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc. San Antonio Marriott Rivercenter
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.
There is no fee to participate in this hybrid event. In order to attend the in-person symposium in San Antonio, you must also be registered to attend the 2023 San Antonio Breast Cancer Symposium®. Preregistration (below) is required as seating is limited for this program. IN-PERSON Registration for clinicians in practice/healthcare professionals
Thank you for your interest in our CME program. At this time online preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our Onsite Registration Desk will be open at 6:45 PM CT on Thursday,, December 7th. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom G-M (Third Floor) of the Marriott Rivercenter hotel (101 Bowie St) within walking distance of the Henry B Gonzalez Convention Center. We will accommodate as many onsite attendees as possible. Seating will be prioritized for clinicians in practice. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153. NOTICE: Registration for this event is independent of registration for the SABCS Conference. LIVE WEBCAST Registration for all professionals
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. REGISTRATION FOR WEBCAST »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. |